X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (104) 104
female (94) 94
middle aged (93) 93
adult (87) 87
oncology (87) 87
aged (86) 86
chemotherapy (61) 61
male (58) 58
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
article (41) 41
human (41) 41
priority journal (37) 37
treatment outcome (37) 37
breast cancer (33) 33
breast neoplasms - drug therapy (31) 31
carcinoma (31) 31
cisplatin (31) 31
antineoplastic combined chemotherapy protocols (30) 30
clinical trial (30) 30
antineoplastic combined chemotherapy protocols - adverse effects (29) 29
cancer (29) 29
paclitaxel (29) 29
survival analysis (27) 27
cancer survival (26) 26
carboplatin (26) 26
index medicus (25) 25
major clinical study (25) 25
controlled study (23) 23
disease-free survival (22) 22
drug administration schedule (22) 22
prognosis (22) 22
aged, 80 and over (21) 21
trial (21) 21
carboplatin - administration & dosage (20) 20
paclitaxel - administration & dosage (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (18) 18
neutropenia (18) 18
therapy (18) 18
anemia (17) 17
cyclophosphamide (17) 17
doxorubicin (17) 17
epirubicin (17) 17
leukopenia (16) 16
neoplasm staging (16) 16
survival (16) 16
survival rate (16) 16
thrombocytopenia (16) 16
adjuvant chemotherapy (15) 15
combined modality therapy (15) 15
disease progression (15) 15
etoposide (15) 15
immunohistochemistry (15) 15
medicine & public health (15) 15
advanced cancer (14) 14
cisplatin - administration & dosage (14) 14
clinical article (14) 14
controlled clinical trial (14) 14
fluorouracil (14) 14
alopecia (13) 13
breast neoplasms (13) 13
retrospective studies (13) 13
breast neoplasms - mortality (12) 12
chemotherapy, adjuvant (12) 12
clinical trials (12) 12
follow up (12) 12
lung neoplasms - drug therapy (12) 12
phase 2 clinical trial (12) 12
breast neoplasms - pathology (11) 11
diarrhea (11) 11
intravenous drug administration (11) 11
metastasis (11) 11
recombinant granulocyte colony stimulating factor (11) 11
research (11) 11
cancer chemotherapy (10) 10
epirubicin - administration & dosage (10) 10
fluorouracil - administration & dosage (10) 10
greece (10) 10
neurotoxicity (10) 10
prospective studies (10) 10
radiotherapy (10) 10
randomized controlled trial (10) 10
trastuzumab (10) 10
anthracyclines (9) 9
antineoplastic agents (9) 9
combination (9) 9
combination chemotherapy (9) 9
drug efficacy (9) 9
febrile neutropenia (9) 9
lung neoplasms (9) 9
methotrexate (9) 9
nausea (9) 9
ovarian cancer (9) 9
ovarian neoplasms - drug therapy (9) 9
phase-iii (9) 9
cancer combination chemotherapy (8) 8
cancer growth (8) 8
etoposide - administration & dosage (8) 8
fatigue (8) 8
granulocyte colony-stimulating factor (8) 8
lung neoplasms - pathology (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 26, pp. 2733 - 2743
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2008, Volume 112, Issue 3, pp. 533 - 543
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1692 - 1698
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 10/2012, Volume 10, Issue 1, pp. 212 - 212
Journal Article
BMC Cancer, ISSN 1471-2407, 08/2008, Volume 8, Issue 1, pp. 234 - 234
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2012, Volume 7, Issue 6, p. e37946
Background: The aim of the present study was to investigate the efficacy of adjuvant dose-dense sequential chemotherapy with epirubicin, paclitaxel, and CMF in... 
PHASE-III TRIAL | COOPERATIVE ONCOLOGY GROUP | NEOADJUVANT CHEMOTHERAPY | MULTIDISCIPLINARY SCIENCES | PROTEIN EXPRESSION | TISSUE MICROARRAYS | BRAIN METASTASES | RISK | DENSE SEQUENTIAL CHEMOTHERAPY | PROGNOSTIC VALUE | DOCETAXEL | Immunohistochemistry | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Methotrexate - therapeutic use | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Cyclophosphamide - therapeutic use | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Young Adult | Disease-Free Survival | Fluorouracil - therapeutic use | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Chemotherapy, Adjuvant - methods | Epirubicin - therapeutic use | Keratin-5 - metabolism | Adult | Female | Aged | Anthracyclines - therapeutic use | Medical research | Anthracyclines | Estrogen | Adjuvant treatment | Breast cancer | Metastasis | Keratin | Paclitaxel | Medicine, Experimental | Rankings | Progesterone | Health aspects | Cancer | Enrichment | Brain | Cytokeratin | Laboratories | Liver | Estrogens | Clinical trials | Estrogen receptors | Oncology | Nervous system | Paraffin | Cancer therapies | Subgroups | Metastases | Proteins | Cell growth | Mastectomy | Bioindicators | Epirubicin | Drug dosages | Risk groups | Epidermal growth factor receptors | Health risks | Patients | Survival | ErbB-2 protein | Medicine | Studies | Pathology | Chemotherapy | Brain research | Hospitals | Anthracycline | Collaboration | Medical prognosis | Biomarkers | Trastuzumab | Tumors
Journal Article
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 7/2015, Volume 23, Issue 7, pp. 2045 - 2051
The aim of this study was to compare the effectiveness of prophylactic single fixed dose of pegfilgrastim and daily administration of filgrastim on febrile... 
Greece | Pain Medicine | Nursing | Rehabilitation Medicine | Medicine & Public Health | Oncology | Breast cancer | Neulasta | Dose-dense chemotherapy | Nursing Management/Nursing Research | Neutropenia | COST-EFFECTIVENESS | COOPERATIVE ONCOLOGY GROUP | COLONY-STIMULATING FACTOR | SOLID TUMORS | RECEIVING CHEMOTHERAPY | PHASE-III | PRIMARY PROPHYLAXIS | ONCOLOGY | FEBRILE NEUTROPENIA | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | DENSE SEQUENTIAL CHEMOTHERAPY | QUALITY-OF-LIFE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Peptides | Polyethylene Glycols | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Chemotherapy-Induced Febrile Neutropenia - prevention & control | Breast Neoplasms - drug therapy | Filgrastim | Recombinant Proteins - administration & dosage | Randomized Controlled Trials as Topic | Breast Neoplasms - blood | Observational Studies as Topic | Female | Retrospective Studies | Chemotherapy, Adjuvant | Naphthalenesulfonates | Cohort Studies | Granulocyte Colony-Stimulating Factor - administration & dosage | Care and treatment | Cancer patients | Granulocyte colony-stimulating factor | Adjuvant treatment | Comparative analysis | Cancer | Comparative studies | Chemotherapy | Preventive medicine | Drug dosages
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, p. e99131
Background: We sought to determine the predictive value of in situ mRNA measurement compared to traditional methods cohort of trastuzumab-treated metastatic... 
CLINICAL-ONCOLOGY/COLLEGE | PROGNOSTIC-FACTOR | MONOCLONAL-ANTIBODY SP3 | MULTIDISCIPLINARY SCIENCES | GENE AMPLIFICATION | POLYMERASE CHAIN-REACTION | HYBRIDIZATION | PARAFFIN-EMBEDDED-TISSUES | AMERICAN-SOCIETY | ONCOTYPE DX TEST | ADJUVANT TRASTUZUMAB | Antibodies, Monoclonal, Humanized - therapeutic use | Receptor, ErbB-2 - genetics | Humans | Middle Aged | RNA, Messenger - genetics | Receptor, ErbB-2 - metabolism | Treatment Outcome | Antineoplastic Agents - therapeutic use | RNA, Messenger - metabolism | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Neoplasm Metastasis | Breast Neoplasms - pathology | Biomarkers, Tumor - metabolism | Adult | Female | Biomarkers, Tumor - genetics | Trastuzumab | Cohort Studies | Measurement | Medical research | Cancer patients | Chemotherapy | RNA | Analysis | Medicine, Experimental | Breast cancer | Metastasis | Cancer | Laboratories | Correlation coefficients | Clinical trials | Oncology | mRNA | Multivariate analysis | Kinases | Cancer therapies | Metastases | Proteins | Regression models | Bioindicators | Correlation coefficient | Internal medicine | Regression analysis | FDA approval | Gene expression | Patients | ErbB-2 protein | Polymerase chain reaction | Medicine | Studies | Pathology | Gene amplification | Hospitals | Correlation analysis | Biomarkers | Breast
Journal Article